Detalhe da pesquisa
1.
UMG1/CD3ε-bispecific T-cell engager redirects T-cell cytotoxicity against diffuse large B-cell lymphoma.
Br J Haematol
; 204(2): 555-560, 2024 02.
Artigo
em Inglês
| MEDLINE | ID: mdl-37963444
2.
Genetic Biomarkers of Sorafenib Response in Patients with Hepatocellular Carcinoma.
Int J Mol Sci
; 25(4)2024 Feb 12.
Artigo
em Inglês
| MEDLINE | ID: mdl-38396873
3.
A Pronectin™ AXL-targeted first-in-class bispecific T cell engager (pAXLxCD3ε) for ovarian cancer.
J Transl Med
; 21(1): 301, 2023 05 04.
Artigo
em Inglês
| MEDLINE | ID: mdl-37143061
4.
The role of brain radiotherapy for EGFR- and ALK-positive non-small-cell lung cancer with brain metastases: a review.
Radiol Med
; 128(3): 316-329, 2023 Mar.
Artigo
em Inglês
| MEDLINE | ID: mdl-36786970
5.
Exploiting DNA Ligase III addiction of multiple myeloma by flavonoid Rhamnetin.
J Transl Med
; 20(1): 482, 2022 10 22.
Artigo
em Inglês
| MEDLINE | ID: mdl-36273153
6.
The New Microtubule-Targeting Agent SIX2G Induces Immunogenic Cell Death in Multiple Myeloma.
Int J Mol Sci
; 23(18)2022 Sep 06.
Artigo
em Inglês
| MEDLINE | ID: mdl-36142133
7.
Exploiting MYC-induced PARPness to target genomic instability in multiple myeloma.
Haematologica
; 106(1): 185-195, 2021 01 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-32079692
8.
Error-prone DNA repair pathways as determinants of immunotherapy activity: an emerging scenario for cancer treatment.
Int J Cancer
; 147(10): 2658-2668, 2020 11 15.
Artigo
em Inglês
| MEDLINE | ID: mdl-32383203
9.
Therapeutic vulnerability of multiple myeloma to MIR17PTi, a first-in-class inhibitor of pri-miR-17-92.
Blood
; 132(10): 1050-1063, 2018 09 06.
Artigo
em Inglês
| MEDLINE | ID: mdl-29997223
10.
The MITO CERV-2 trial: A randomized phase II study of cetuximab plus carboplatin and paclitaxel, in advanced or recurrent cervical cancer.
Gynecol Oncol
; 153(3): 535-540, 2019 06.
Artigo
em Inglês
| MEDLINE | ID: mdl-30979589
11.
Systematic review and meta-analysis on targeted therapy in advanced pancreatic cancer.
Pancreatology
; 16(2): 249-58, 2016.
Artigo
em Inglês
| MEDLINE | ID: mdl-26852170
12.
Phase I trial of thymidylate synthase poly-epitope peptide (TSPP) vaccine in advanced cancer patients.
Cancer Immunol Immunother
; 64(9): 1159-73, 2015 Sep.
Artigo
em Inglês
| MEDLINE | ID: mdl-26031574
13.
A p53-dependent tumor suppressor network is induced by selective miR-125a-5p inhibition in multiple myeloma cells.
J Cell Physiol
; 229(12): 2106-16, 2014 Dec.
Artigo
em Inglês
| MEDLINE | ID: mdl-24819167
14.
The impact of PARP inhibitors in the whole scenario of ovarian cancer management: A systematic review and network meta-analysis.
Crit Rev Oncol Hematol
; 193: 104229, 2024 Jan.
Artigo
em Inglês
| MEDLINE | ID: mdl-38065404
15.
Identification of ADME genes polymorphic variants linked to trastuzumab-induced cardiotoxicity in breast cancer patients: Case series of mono-institutional experience.
Biomed Pharmacother
; 174: 116478, 2024 May.
Artigo
em Inglês
| MEDLINE | ID: mdl-38547766
16.
Pharmacological inhibition of HSP90 and ras activity as a new strategy in the treatment of HNSCC.
J Cell Physiol
; 228(1): 130-41, 2013 Jan.
Artigo
em Inglês
| MEDLINE | ID: mdl-22566192
17.
miR-29b negatively regulates human osteoclastic cell differentiation and function: implications for the treatment of multiple myeloma-related bone disease.
J Cell Physiol
; 228(7): 1506-15, 2013 Jul.
Artigo
em Inglês
| MEDLINE | ID: mdl-23254643
18.
The emerging scenario of immunotherapy for T-cell Acute Lymphoblastic Leukemia: advances, challenges and future perspectives.
Exp Hematol Oncol
; 12(1): 5, 2023 Jan 09.
Artigo
em Inglês
| MEDLINE | ID: mdl-36624522
19.
Targeting non-coding RNAs: Perspectives and challenges of in-silico approaches.
Eur J Med Chem
; 261: 115850, 2023 Dec 05.
Artigo
em Inglês
| MEDLINE | ID: mdl-37839343
20.
First-line systemic treatment for hepatocellular carcinoma: A systematic review and network meta-analysis.
Heliyon
; 9(8): e18696, 2023 Aug.
Artigo
em Inglês
| MEDLINE | ID: mdl-37560704